Keyword Connections

primary myelofibrosis

Journals

6

1 OncoTargets and therapy

2 Cancer medicine

3 hematological oncology

4 European journal of neurology

5 journal of the national comprehensive cancer network : jnccn

6 biology of blood and marrow transplantation : journal of the american society for blood and marrow transplantation

Research Groups

0

No Research Group Connected

Bibliographies

27

1 t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma.

2 Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.

3 Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

4 Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.

5 Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.

6 Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?

7 ruxolitinib treatment in a patient with primary myelofibrosis resistant to conventional therapies and splenectomy: a case report

8 the european clinical, molecular, and pathological (ecmp) criteria and the 2007/2008 revisions of the world health organization for the diagnosis, classification, and staging of prefibrotic myeloproliferative neoplasms carrying the jak2v617f mutation

9 Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management

10 Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

11 Recent advances in the diagnosis and management of primary myelofibrosis

12 Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement

13 Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management

14 Zoledronic acid administration is effective for hematopoiesis management in a patient with primary myelofibrosis

15 Actualities in the management of primary myelofibrosis

16 Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors

17 Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT/ELN international working group

18 Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

19 Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management

20 Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis

21 Erratum to Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

22 Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

23 Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management

24 Advances in the understanding and management of primary myelofibrosis

25 Diagnostic and therapeutic progress in the management of primary myelofibrosis

26 generation and characterization of a human induced pluripotent stem (ips) cell line derived from an acute myeloid leukemia patient evolving from primary myelofibrosis carrying the calr 52 bp deletion and the asxl1 p.r693x mutation

27 ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the budd-chiari syndrome.